ResearcherSun Yat-sen UniversityActive in the last 2 years
Qiuxia Yang
Matched on ORCID iD 0000-0002-2852-3925; OpenAlex author ID A5011854155. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper
Papers 6
- Semi-automatic fine delineation scheme for pancreatic cancer. First author DOI 10.1002/mp.16718↗
- Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. First author DOI 10.2147/jir.s404900↗
- The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ygeno.2021.11.036↗
- Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Analysis. Co-author DOI 10.1200/po.21.00362↗
- Are left ventricular muscle area and radiation attenuation associated with overall survival in advanced pancreatic cancer patients treated with chemotherapy? Co-author DOI 10.1016/j.crad.2019.11.003↗
- A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.2526↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yize Mao · 4 shared papers, 2019–2023 · strength 0.59
- Paper Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. DOI 10.2147/jir.s404900↗
- Paper Identifying Outcomes of Patients With Advanced Pancreatic Adenocarcinoma and RECIST Stable Disease Using Radiomics Anal… DOI 10.1200/po.21.00362↗
- Paper The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.ygeno.2021.11.036↗
- Shengping Li · 3 shared papers, 2019–2023 · strength 0.44
- Paper Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer. DOI 10.2147/jir.s404900↗
- Paper The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. DOI 10.1016/j.ygeno.2021.11.036↗
- Paper A feasible CT feature to differentiate focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. DOI 10.1002/cam4.2526↗
- Lizhi Liu · 2 shared papers, 2022–2024 · strength 0.36
- Weizong Zhan · 1 shared paper, 2024 · strength 0.21
- Hongbo Chen · 1 shared paper, 2024 · strength 0.21
- Honglu Ding · 1 shared paper, 2023 · strength 0.19
- Dailei Qin · 1 shared paper, 2023 · strength 0.19
- Zehui Yao · 1 shared paper, 2023 · strength 0.19
- Ruiqi L. Wang · 1 shared paper, 2023 · strength 0.19
- Yong Li · 1 shared paper, 2022 · strength 0.15
- Tao Qin · 1 shared paper, 2022 · strength 0.15
- Rong Zhang · 1 shared paper, 2022 · strength 0.15
- Wei Wang · 1 shared paper, 2022 · strength 0.15
- Liqin Li · 1 shared paper, 2022 · strength 0.15
- Qing Cai · 1 shared paper, 2020 · strength 0.13
- R. Zhang · 1 shared paper, 2020 · strength 0.13
- Dailin Rong · 1 shared paper, 2019 · strength 0.10
- Chaobin He · 1 shared paper, 2019 · strength 0.10
- Yanchun Lv · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.